NICE NG100 2020: rheumatoid arthritis management in adults

Who it applies to

Adults with suspected or confirmed rheumatoid arthritis managed in primary and secondary care, including specialist rheumatology services.

Key recommendations

• Refer adults with suspected persistent synovitis of undetermined cause urgently to a rheumatologist for specialist opinion, rather than waiting for investigation results.
• Offer first-line treatment with a conventional DMARD (such as methotrexate, leflunomide, or sulfasalazine) as monotherapy as soon as possible, ideally within 3 months of persistent symptom onset.
• Consider short-term bridging glucocorticoid therapy when starting a new conventional DMARD to control symptoms while the DMARD takes effect.
• Monitor disease activity regularly using a composite measure such as a validated joint count and inflammatory marker score, and escalate treatment if targets are not met (treat-to-target approach).
• Step up to combination conventional DMARD therapy if monotherapy does not adequately control disease activity.
• Reserve biological DMARDs (including TNF inhibitors) for people who have had an inadequate response to combination conventional DMARDs, in line with relevant NICE technology appraisals.
• Offer access to multidisciplinary care, including physiotherapy, occupational therapy, and podiatry, to support function and manage joint-related complications.
• Provide patients with education and self-management advice, including information on managing flares and when to seek urgent review.
• Assess cardiovascular risk periodically, as rheumatoid arthritis is an independent risk factor, and manage risk factors accordingly.
• Review drug therapy regularly for toxicity and offer appropriate monitoring blood tests for DMARDs, particularly methotrexate.

Practice points for students

• Early aggressive DMARD therapy within the window of opportunity is key to preventing joint damage.
• Treat-to-target means regular objective reassessment of disease activity, not just symptom-based review.
• Combination conventional DMARDs are tried before stepping up to biologics, unless contraindicated.
• Patients on methotrexate need routine monitoring bloods due to hepatotoxicity and bone marrow suppression risk.
• Multidisciplinary input (physio, OT, podiatry) is part of standard rheumatoid arthritis care, not an optional extra.

Condition

Other guidelines on this topic

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 updateEULAR2026Official guideline
• 2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid ArthritisACR2023Official guideline

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by NICE. It is not medical advice: always read the original guideline before applying it to patients.